From the Departments of Cardiology, Sourasky-Tel-Aviv Medical Center
(B.B., R.F., A.G., S.L., S.V.) and Sheba Medical Center (M.G., M.E.), Sackler
School of Medicine, Tel-Aviv University, Israel.
Correspondence to Bernard Belhassen, MD, Department of Cardiology, Tel-Aviv Medical Center, Weizman St 6, Tel-Aviv 64239, Israel. E-mail belhasen{at}ccsg.tau.ac.il
Methods and ResultsDuring
electrophysiological study, we
intravenously administered incremental doses of ATP (from
10 to 50 mg) during sinus rhythm to patients with spontaneous and
inducible sustained AVNRT (study group, n=42) and to patients with no
evidence of dual AV nodal physiology or inducible AVNRT (control group,
n=21). Signs suggestive of dual AV node physiology after ATP
administration during sinus rhythm ("jump" of AH
ConclusionsAdministration of ATP during sinus rhythm may be a
useful bedside test for identifying patients with dual AV nodal
pathways who are prone to AVNRT. This simple test should be considered
as a screening test for patients with symptoms suggestive of paroxysmal
supraventricular tachycardia but no documented
arrhythmias or for patients with documented narrow complex
tachycardia of unclear mechanism.
Electrophysiological Study
Definitions
Ablation Procedure
ATP Test
The ATP test was first performed after completion of the baseline
electrophysiological study. Whenever
isoproterenol administration was used during the baseline study, the
ATP test was performed after discontinuation of isoproterenol infusion
and return of the sinus rate to baseline.
The ATP test was repeated in a subset of patients who underwent
radiofrequency ablation or modification of the slow pathway. Assessment
of AV nodal conduction (for differentiation between slow AV nodal
pathway ablation or modification) after the ablative procedure always
involved infusion of isoproterenol. The ATP test performed after the
ablative procedure was performed only after discontinuation of
isoproterenol and return of the sinus rate close to the preinfusion
sinus rate.
Definitions Used During the ATP Test
Statistics
ATP Test
A sudden and transient increment in AH interval (
AV nodal echoes (range, 1 to 8; mean, 2.2±1.6 beats) after ATP
injection were observed in 20 (48%) study patients (Figs 1A
Signs of dual AV node physiology (any of the above) were observed after
ATP injection in 32 (76%) of the study patients. For comparison, only
1 (5%) of the 21 control patients had any signs suggestive of dual AV
node physiology during the ATP test (P<0.001). Accordingly,
the presence of dual AV node physiology (as suggested by the ATP test)
correlated with the presence of inducible AVNRT with a sensitivity and
specificity of 76% and 100%, respectively.
Similar results were obtained when only surface lead
recordings, without intracardiac electrograms, were evaluated.
All patients with a sudden
Correlation of ATP Test With Electrophysiological Data
Correlation of ATP Test With Ablation Results
Safety
Study Population
Diagnostic Value of ATP Test
Electrophysiological Correlations
Correlations With Ablation Results
Safety
Limitations
Clinical Implications
Received December 1, 1997;
revision received February 18, 1998;
accepted March 1, 1998.
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports
Noninvasive Diagnosis of Dual AV Node Physiology in Patients With AV Nodal Reentrant Tachycardia by Administration of Adenosine-5'-Triphosphate During Sinus Rhythm
![]()
Abstract
Top
Abstract
Introduction
Methods
Results
Discussion
References
BackgroundAtrioventricular
nodal reentry tachycardia (AVNRT) represents the
most commonly encountered type of regular paroxysmal
supraventricular tachycardia. This study
determined whether administration of adenosine-5'-triphosphate
(ATP) during sinus rhythm may be useful in the noninvasive diagnosis of
dual AV nodal pathways.
50 ms between 2
consecutive beats,
1 AV nodal echo beat, or initiation of AVNRT) were
observed in 32 (76%) of 42 study patients but in only 1 (5%) of the
21 control patients (P<0.001). Similar results were
observed when only surface lead recordings (without
intracardiac recordings) were evaluated. Signs suggestive of
dual AV node physiology by the ATP test were observed in 29 (80.5%) of
36 patients who had electrophysiological
demonstration of dual AV node physiology and in 3 (50%) of 6 patients
without AV nodal duality (P=NS). Signs suggestive of
dual physiology according to the ATP test disappeared in 11 (92%) of
the 12 patients who underwent successful slow AV nodal ablation but
persisted in 8 (62%) of 13 patients who underwent AV nodal
modification.
Key Words: arrhythmia tachycardia electrophysiology
![]()
Introduction
Top
Abstract
Introduction
Methods
Results
Discussion
References
Adenosine
5'-triphosphate is a very effective drug for terminating
atrioventricular nodal reentry tachycardia
(AVNRT).1 2 The
electrophysiological effects of ATP during
AVNRT have been studied previously.1 ATP
terminates the typical slow/fast form of AVNRT mainly due to antegrade
block in the slow AV nodal pathway, with no or minimal effect on the
fast retrograde nodal pathway. Less is known, however, about the
effects of the administration of ATP during sinus rhythm in patients
with AVNRT. Because the refractory period of the antegrade fast pathway
is usually longer than that of the antegrade slow pathway, we
speculated that (1) ATP would affect these two pathways differently
during sinus rhythm, and (2) this difference in
electrophysiological effects could prove to
be useful in the noninvasive diagnosis of dual AV nodal physiology.
Thus, we evaluated the effects of ATP administration during sinus
rhythm in patients with typical AVNRT and compared them with those
observed in a control group of patients without antegrade dual AV node
physiology or inducible AVNRT. In addition, in a subset of patients who
underwent radiofrequency catheter ablation or modification of the slow
AV nodal pathway, we compared the effects of the administration of ATP
during sinus rhythm before and after the procedure.
![]()
Methods
Top
Abstract
Introduction
Methods
Results
Discussion
References
Patient Population
The study group consisted of consecutive patients with
spontaneous paroxysmal supraventricular
tachycardia (PSVT) referred for radiofrequency ablation who
had inducible sustained AVNRT. All patients in the study group had the
slow/fast form of AVNRT induced with no drug or after
intravenous administration of isoproterenol. The control
group consisted of consecutive patients who underwent successful
radiofrequency ablation of an accessory pathway and who did not have
inducible AVNRT or demonstrable antegrade dual AV node physiology by
standard electrophysiological criteria (see
below). All patients were evaluated in the absence of antiarrhythmic
drug therapy. None of the patients had a history of asthma, a
contraindication for ATP administration, or were treated with drugs
known to markedly interfere with ATP metabolism (eg,
aminophylline or dipyridamole).
After informed consent was obtained from patients, the
electrophysiological study was performed
with the use of standard techniques. Two 6F quadripolar electrode
catheters (Bard, USCI) were introduced percutaneously
through the right femoral vein and positioned in the right
ventricular apex and the His bundle area, respectively. A
6F decapolar electrode catheter (Bard, USCI) was introduced into the
coronary sinus, usually after catheterization
of a left antecubital vein. The baseline
electrophysiological study included the
following: (1) delivery of 1 to 3 extrastimuli during sinus rhythm from
the proximal coronary sinus until the atrial or AV nodal
refractory period was reached; (2) incremental proximal
coronary sinus pacing up to the AV nodal block cycle length;
and (3) incremental rapid ventricular apical pacing up to
the ventriculoatrial block cycle length. If sustained
tachycardia was not induced by use of this protocol,
isoproterenol was administered at incremental dosage until the basic
sinus rhythm increased by
20%, and the stimulation protocol was
repeated.
Dual AV node physiology was defined as a
50-ms increment in
AsH value after a 10-ms decrement in A-As interval during single atrial
extrastimulation (As) during sinus rhythm (cycle length AA) or a
50-ms increment in AH or AV value in consecutive beats after a
10-ms decrement in pacing cycle length during overdrive atrial
pacing. Absence of AV node physiology was defined as the failure to
demonstrate dual AV node physiology (defined as above) during
coronary sinus pacing up to the AV nodal block cycle length or
by atrial extrastimulation until AV nodal refractoriness was reached.
In patients in whom the refractory period of the fast pathway could be
determined during sinus rhythm, it was defined as the longest A-As
interval that resulted in conduction over the slow AV nodal
pathway.
Radiofrequency ablation of the slow AV nodal pathway was
performed according to a standard
electrophysiological-anatomic
approach.3 Ablation of the slow pathway was
considered achieved when, after radiofrequency application, both of the
following criteria were present: (1) dual AV node physiology could
no longer be demonstrated and (2) neither AV nodal echos nor AVNRT
could be induced despite multiple trials of atrial extrastimulation
(with up to 3 extrastimuli) and multiple trials of rapid atrial pacing
(repeatedly performed during a 10-minute period) with and without
isoproterenol infusion. Modification of the slow pathway was defined as
the persistence of dual AV node physiology but without inducible AVNRT
(
1 AV nodal echo beat) with and without isoproterenol.
This protocol was approved by our Ethical Committee, and all
patients gave informed consent. The effects of ATP on AV nodal
conduction were evaluated during sinus rhythm. ATP (Striadyne, Wyeth
Laboratories) was injected through the right antecubital vein as a
rapid bolus followed by a 20-mL flush of normal saline. The initial
dose of ATP was 10 mg. Repeated doses (with 10-mg increments) were
given at 2- to 3-minute intervals until one of the following
prospectively defined end points was observed: (1) signs of dual AV
node physiology during ATP administration (see below) or 2) second- or
third-degree AV block. The test was discontinued if severe clinical
intolerance or sinus bradycardia causing >3-second pause occurred. The
latter patients were excluded from final analysis. Once one of
the study end points (signs of dual AV node physiology or AV block) was
achieved for a particular dose of ATP, the reproducibility of the test
was assessed with the use of an identical dose of ATP. If the second
dose of ATP failed to achieve the same end point, a third identical
dose of ATP was tested, and the definite result taken for
analysis was the one observed in 2 of 3 ATP tests. The results
taken for final analysis were those associated with the more
pronounced effects.
Signs of dual AV node physiology during ATP administration were
considered to be present when
1 of the following events occurred
after ATP injection: (1) AH interval increased by
50 ms between 2
consecutive sinus beats; (2) an AV nodal echo beat was considered to be
present; or (3) AVNRT developed. Diagnoses of AVNRT and AV nodal
echo beat were based on intracardiac recordings. In addition,
to evaluate the diagnostic value of the ATP test performed
as a bedside test (using surface ECG leads only), recordings of
surface leads I, II, III, and V1 were
subsequently analyzed by 2 investigators who were blinded to
the patients' group assignments and to the simultaneous
intracardiac recordings. Single AV nodal echoes are often
difficult to discern without the aid of intracardiac
recordings. However, AV nodal echoes would be expected to reset
the sinus firing rate. Therefore, AV nodal echoes were considered to be
present when, after a sinus complex conducted with increased PR
interval, a >70% increment in P-P interval was seen or retrograde P
waves were seen at the end of the QRS complex.
Statistical comparison of
electrophysiological results in the study
and control groups was performed by use of Fisher's exact test. Data
were expressed as mean±SD. A value of P<0.05 was
considered statistically significant.
![]()
Results
Top
Abstract
Introduction
Methods
Results
Discussion
References
Patient Population
Sixty-seven patients underwent evaluation of the effects of ATP
during sinus rhythm. None of these patients had evidence of organic
heart disease. Four patients (6%) (2 from the study group and 2 from
the control group) were excluded because of intolerance to ATP. The
remaining 63 patients completed the ATP test. The study group consisted
of 42 patients (29 females, 13 males; age, 42±13 years) with inducible
sustained, typical (slow/fast) AVNRT. The control group consisted of 21
patients (15 males, 6 females; age, 31±11 years) who had no evidence
of dual AV node physiology or inducible AVNRT after radiofrequency
ablation of an accessory pathway. Dual AV node physiology was
demonstrated in 36 (86%) of the 42 study group patients and was not
apparent (by atrial extrastimulation or overdrive pacing) in the
remaining 6 (14%).
In the 63 patients who completed the ATP test, the ATP doses
required to reach 1 of the end points in the study and control groups
were 19.3±8.5 mg (range, 10 to 50 mg ATP) and 20.4±9.9 mg (range, 10
to 40 mg), respectively (P=NS). A similar proportion of
patients from the study group (27 of 42; 64%) and the control group
(15 of 21; 71%) were given
20 mg of ATP. The effects of ATP
typically began
10 seconds after bolus administration, were maximal
within the next 5 to 10 seconds, and were always short lasting (<1
minute).
50 ms) after ATP
injection during sinus rhythm was observed in 32 (76%) of the 42
patients in the study group (Fig 1A
) but
in only 1 (5%) of the 21 control patients (P<0.001) (Fig 2
). The maximal AH increment between 2
consecutive beats was significantly greater in the study group (127±97
ms) than in the control group (17±14 ms) (P<0.001) (Fig 3
). In the 32 patients who had an AH
increment of
50 ms after ATP administration, this AH increment ranged
from 50 to 400 ms (mean, 162±70 ms), and the number of beats with
suspected conduction over a slow AV nodal pathway ranged from 1 to 17
(mean, 4.1±3.4) (Fig 1A
). The single control patient who manifested an
AH increment
50 ms had a 60-ms increment.

View larger version (45K):
[in a new window]
Figure 1. Effects of ATP (20 mg) on AV conduction before and
after radiofrequency ablation of the slow pathway in a patient with AV
nodal reentrant tachycardia. A, Before slow pathway
ablation, dual AV node physiology is present during ATP test. AH
interval increases by 80 ms on the second beat, and 1 AV nodal echo
beat occurs on the fourth beat. A similar sequence of events (AH
prolongation and AV nodal echo beats) is seen on subsequent beats. B,
Abolition of dual AV node physiology during ATP test after
radiofrequency ablation of slow AV nodal pathway. A transient 2:1 to
3:1 AV nodal block is observed associated with minimal prolongation of
AH interval (20 ms) on 2 conducted consecutive beats (the first 2 beats
of the tracing). No AV nodal echos are observed. HBE indicates His
bundle electrogram; CS, coronary sinus electrogram.

View larger version (40K):
[in a new window]
Figure 2. Lack of dual AV node physiology after
administration of 10 mg ATP in a patient from control group.
Progressive AH prolongation with AH increment
50 ms is observed,
followed by a short-lasting 2:1 AV nodal block. HBE indicates His
bundle electrogram; CS, coronary sinus electrogram.

View larger version (14K):
[in a new window]
Figure 3. Maximal AH jump between 2 consecutive beats
(
AH) after ATP administration in all patients from study and control
groups.
, 4B
, and 4C
) but in none of the control
patients (P<0.001) (Fig 2
). Interestingly, administration
of ATP during sinus rhythm provoked episodes of sustained AVNRT
(lasting >30 seconds) in 3 (7%) patients in the study group (Fig 4A
).
These episodes of AVNRT were triggered by premature atrial beats in 2
patients and initiated from sinus rhythm in the third patient.

View larger version (45K):
[in a new window]
Figure 4. Occurrence of AV nodal reentrant
tachycardia (AVNRT) during ATP test. A,
6 seconds (T 6s)
after a bolus administration of 20 mg ATP, a premature atrial beat
(arrow) initiates AVNRT, which lasted 7 seconds. B, At T 13s, AVNRT
terminates owing to block in the antegrade slow pathway. After
tachycardia termination, a few slow/fast AV nodal echo
beats are observed. C, At T 23s, sinus rhythm with 1:1 conduction over
the fast AV nodal pathway resumes. HBE indicates His bundle
electrogram; CS, coronary sinus electrogram.
50-ms increment in AH after ATP
administration were correctly identified (by the presence of a similar
increment in PR interval) by the investigators who looked only at
surface leads. All instances of ATP-induced AV nodal echoes were
correctly identified with our prospectively defined ECG criteria (a
>70% increment in P-P interval or appearance of retrograde P waves at
the end of the QRS complex after a sinus beat conducted with a long
PR). Although these ECG criteria led to misdiagnosis of AV nodal echoes
in 2 study patients, other signs of dual AV node physiology after ATP
injection were correctly identified with surface lead
recordings in these patients. Thus, the sensitivity and
specificity of the ATP test using surface leads only (without
intracardiac recordings) for identifying patients with AVNRT
were the same as those obtained with the aid of intracardiac
recording.
Of the 36 study patients who had
electrophysiological demonstration of dual
AV node physiology, 29 (80.5%) had signs of dual AV node physiology
suggested by ATP test. Of the remaining 6 patients in the study group
who had no electrophysiological evidence of
dual AV node physiology, 3 (50%) had signs of dual AV node physiology
suggested by ATP test (P=NS). In patients with
electrophysiological AV node duality, there
was no correlation between the atrial pacing cycle length inducing
block in the fast pathway and the results of the ATP test (398±89 ms,
n=29 and 371±90 ms, n=7 for patients with positive and negative ATP
tests, respectively). Comparison between the refractory period of the
fast pathway during sinus rhythm and results of the ATP test was not
performed due to the small number of patients.
Successful radiofrequency ablation or modification of the slow AV
nodal pathway was achieved in all but 1 of the study patients. After
completion of radiofrequency therapy, the ATP test was repeated in a
subset of 25 consecutive patients, including 12 who underwent ablation
and 13 who underwent modification of the slow AV nodal pathway. All
these patients had signs suggestive of dual AV node physiology
according to the ATP test performed at baseline (before the ablation
procedure). After the ablation procedure, signs suggestive of dual
physiology according to the ATP test disappeared in 11 (92%) of the 12
patients who had slow AV nodal ablation (Fig 1B
) but persisted in 8
(62%) of 13 patients with AV nodal modification.
Only 4 patients (2 from each group) were excluded from the study
because of ATP intolerance. These patients developed intolerable
dyspnea, before an end point was observed, after injection of 30 (1
patient) and 50 mg (3 patients) of ATP. In addition, transient complete
AV block (lasting <5 seconds) occurred in 4 and 2 patients in the
study and control groups, respectively. The bradycardia was well
tolerated by all patients and did not require any intervention. Minor
side effects (eg, flushing, tolerable dyspnea) occurred commonly but
were self-terminating, lasting <1 minute in all instances.
![]()
Discussion
Top
Abstract
Introduction
Methods
Results
Discussion
References
Main Findings
Although spontaneous ECG manifestations compatible with dual AV
nodal conduction are uncommon,4 we describe a
noninvasive diagnostic test that uses administration of ATP
to identify patients with dual AV nodal pathways who are prone to
AVNRT. Administration of ATP during sinus rhythm revealed signs
suggestive of dual AV node physiology in a high percentage (76%) of
patients with inducible sustained AVNRT but in only 5% of the control
group. Moreover, identification of patients with AVNRT could be
performed with the same accuracy (sensitivity of 76% and specificity
of 100%) when the ATP test was evaluated with surface ECG
recordings (without intracardiac recordings). This
suggests that the ATP test may be a useful bedside test for identifying
patients prone to AVNRT.
A sudden increment in AH interval of
50 ms after a 10-ms
decrement during single atrial extrastimulation testing is considered
indicative of the presence of dual AV node
physiology.5 Extrastimulus testing is typically
performed during atrial pacing (at
1 constant basic cycle lengths)
and is performed from
1 atrial sites.6 In the
present study, extrastimulus testing was performed only during
sinus rhythm from a single pacing site (proximal coronary
sinus). In addition, increase in AH interval of
50 ms for a 10-ms
decrement in pacing cycle length was also taken as indicative of the
presence of dual AV node physiology. When such definitions were used,
the incidence of dual AV node physiology in our patients (86%) was
similar to the 85% incidence found by Josephson in a
review,7 suggesting that our study group is
representative of the population of patients with
typical slow/fast AVNRT.
We prospectively defined a 50-ms increment in the AH interval
between 2 consecutive sinus beats after ATP administration as
suggestive of dual AV node physiology. Selection of this 50-ms value as
a cutoff point may seem rather arbitrary. This definition, however, is
analogous to the one used to define duality during
electrophysiological
testing.5 In fact, the magnitude of the jump in
AH interval observed in patients with AVNRT after ATP administration
was far more impressive in the majority of study patients. In other
words, whenever the presence of duality was suggested after ATP
administration, the jump was obvious (mean AH increment of 162±70 ms)
and relatively long lasting (observed on a mean of 4 beats). Moreover,
AV nodal echoes occurred in 62% of patients demonstrating a
50-ms
jump, and even sustained episodes of AVNRT were triggered in a few
patients after ATP injection. This strongly suggests that the sudden
increment in AH interval that followed ATP injection during sinus
rhythm indeed represented ATP-induced blockade of the fast
AV nodal pathway with subsequent conduction over the slow AV nodal
pathway rather than merely decremental AV nodal conduction.
We found no correlation between the presence of duality (by ATP
criteria) and the cycle length at which blockade of the fast AV nodal
pathway occurred during atrial overdrive pacing, suggesting that the
response to ATP does not depend on the antegrade refractoriness of the
fast pathway. More interestingly, signs of dual AV node physiology were
observed after ATP administration in 3 of our 6 study patients who did
not have electrophysiological evidence of
dual physiology. This observation is consistent with the report
of Sheahan et al8 on the
electrophysiological effects of
radiofrequency ablation of the slow pathway in patients without
discontinuous curves of AV nodal conduction who nevertheless have
AVNRT. These workers concluded that the apparently "smooth" AV node
refractory curve consists, in fact, of two distinct components
representing both fast and slow AV node pathways, even when
the typical discontinuity is absent.
Successful radiofrequency ablation of the slow pathway is
associated with either total elimination of antegrade conduction over
the slow pathway or its "modification."3 The
last term is used to denote the fact that despite the persistence of
antegrade slow pathway conduction, no more than a single AV nodal echo
beat can be induced, even after isoproterenol
administration.3 In the present study, the
results of the ablation procedure correlated with the results of the
postablation ATP test. Signs of dual AV node physiology after the ATP
test disappeared in 11 (92%) of 12 patients after elimination of the
slow pathway but persisted in 8 (62%) of 13 patients after
modification of the slow pathway. Rather than repeating the ATP test
after each radiofrequency application, we performed a second ATP test
only at the end of the electrophysiological
study, whenever either complete elimination or at least modification of
slow AV nodal conduction was thought to have been achieved. Therefore,
we have no data on the value of the ATP test to predict unsuccessful
ablation (persistence of inducibility of AVNRT).
The safety of ATP administration during PSVT is well
established.1 2 Recently, Flammang et
al9 provided data on the safety of ATP injection
during sinus rhythm. In this study, cardiac pauses lasting
10 seconds
were observed in 3 (6%) of 51 healthy control subjects who received a
single injection of 20 mg of ATP. Although 41 (67%) of our patients
received ATP at dosages of
20 mg, pauses lasting >5 seconds were
never observed. The difference in the definition of "pauses" used
in the different studies should be noted. Flammang et al ignored single
escape beats and measured the total pause between conducted sinus
beats, whereas we measured the longest pause between
ventricular complexes (sinus beats or escape beats).
Moreover, acute interventions were never required after ATP-induced
pauses in either of the 2 studies. Nevertheless, the ATP test should
always be performed under close ECG observation.
ATP administration was not performed during constant atrial
pacing, which would have avoided the ATP-related changes in sinus rate
and could have enabled a better quantification of the changes in AV
conduction. Instead, we preferred to administer ATP during sinus rhythm
to make the test more readily applicable for clinical bedside use.
ATP has already been successfully used in the noninvasive
diagnosis of several arrhythmia disorders, such as the
differential diagnosis of wide QRS complex
tachycardia.10 ATP has also been used
during sinus rhythm to establish the diagnosis of Wolff-Parkinson-White
syndrome in patients with a minor degree of preexcitation or to assess
the results of an ajmaline test in patients with
preexcitation.11 More recently, injection of ATP
was recommended to select treatment in patients with severe vasovagal
syndrome.9 The results of the present study
suggest that ATP may also be useful in the noninvasive diagnosis of
dual AV node physiology in patients prone to AVNRT. Although the
diagnosis of the slow/fast form of AVNRT is usually easy when a
good-quality 12-lead ECG, recorded during a spontaneous episode, is
available, it may be difficult if the tracing is of poor quality or if
only 1 or 2 ECG leads (for example, from Holter or telemetry
recordings) are available. The ATP test may be useful in the
latter case, and additional studies are warranted to test this
possibility. Another potential field of research on the ATP test may be
the group of patients with normal resting ECGs and undocumented
palpitations suggestive of PSVT. Because AVNRT is by far the most
common mechanism of PSVT, the results of the test may help in selecting
patients for diagnostic
electrophysiological study and
radiofrequency therapy. Our study did not include patients with other
forms of narrow complex tachycardia. Thus, we cannot
elaborate on the value of this test for identifying or excluding other
arrhythmia mechanisms. Obviously, a negative ATP test would not
exclude the possibility that other arrhythmias (such as AV
reentry involving a concealed bypass) are responsible for the
patient's symptoms. Nevertheless, a positive ATP test would be
valuable because radiofrequency therapy of AVNRT is generally less time
consuming than evaluation and radiofrequency therapy of patients with
other arrhythmias. Accordingly, patients with a positive ATP
test could be allotted less time when the
electrophysiological laboratory is
scheduled. Finally, although the
electrophysiological effects of ATP in
humans are in great part due to adenosine, the final
product of the degradation of ATP, our results are only applicable
for ATP. Because of conflicting data regarding the involvement of the
vagus nerve in the mechanism of action of ATP in the human
heart,12 one cannot exclude that a vagal
component involved in ATP effects in humans played a role in our
findings. Because adenosine rather than ATP is commonly used in
the United States for the treatment of PSVT, additional studies of the
effects of adenosine in the noninvasive diagnosis of dual AV
node physiology are warranted.
![]()
References
Top
Abstract
Introduction
Methods
Results
Discussion
References
This article has been cited by other articles:
![]() |
S. Viskin, R. Rosso, O. Rogowski, B. Belhassen, A. Levitas, A. Wagshal, A. Katz, D. Fourey, D. Zeltser, A. Oliva, et al. Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndrome Eur. Heart J., February 2, 2006; 27(4): 469 - 475. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Heinroth, K. Kattenbeck, I. Stabenow, H.-J. Trappe, and P. Weismuller Multiple AV nodal pathways in patients with AV nodal reentrant tachycardia -- more common than expected? Europace, January 1, 2002; 4(4): 375 - 382. [Abstract] [PDF] |
||||
![]() |
S C Toal, B U Vajifdar, A K Gupta, A M Vora, and Y Y Lokhandwala Adenosine induced PR jump on surface ECG to differentiate atrioventricular nodal re-entrant tachycardia from concealed accessory pathway mediated tachycardia: a bedside test Heart, January 1, 2002; 87(1): 37 - 40. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Viskin, R. Fish, A. Glick, M. Glikson, M. Eldar, and B. Belhassen The adenosine triphosphate test: a bedside diagnostic tool for identifying the mechanism of supraventricular tachycardia in patients with palpitations J. Am. Coll. Cardiol., July 1, 2001; 38(1): 173 - 177. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D'Este, E. Bertaglia, A. Zanocco, B. Reimers, and P. Pascotto Electrophysiological properties of the atrioventricular node and ageing: evidence of a lower incidence of dual nodal pathways in the elderly Europace, January 1, 2001; 3(3): 216 - 220. [Abstract] [PDF] |
||||
![]() |
B. Belhassen, R. Fish, S. Viskin, A. Glick, M. Glikson, and M. Eldar Adenosine-5'-triphosphate test for the noninvasive diagnosis of concealed accessory pathway J. Am. Coll. Cardiol., September 1, 2000; 36(3): 803 - 810. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |